AstraZeneca Plc saw revenue advance by 5% to $6,542 million in the third quarter – its third consecutive quarter of growth. However operating profit was down by 68% at $541 million, and earnings per share fell more steeply by 80% to $0.20, both on a reported basis. This reflected a spike in research and development spending and a higher cost of sales.
